Monte Rosa Therapeutics GLUE
NASDAQ GLUE
$10.45 -0.81 (-7.19%)
As of: Oct 2, 2026 · 2:27 PM EDT

Monte Rosa Therapeutics (GLUE) Depreciation & Amortization (CF) (2020 - 2026)

Updated

Monte Rosa Therapeutics (GLUE) posted Depreciation & Amortization (CF) of $1.91 million for Q2 2026, down 10.1% from $2.13 million a year earlier and down 5.8% from the prior quarter.

Analysis

Monte Rosa Therapeutics (GLUE) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, Depreciation & Amortization (CF) at Monte Rosa Therapeutics was $8.17 million, down 2.0% year-over-year; for FY2025, it came in at $8.4 million, up 3.4% from FY2024.

  • Annual Depreciation & Amortization (CF) has increased for five consecutive years, with a five-year compound annual growth rate of 73.3% (FY2020 to FY2025).
  • In prior years, Monte Rosa Therapeutics' Depreciation & Amortization (CF) was $8.12 million in FY2024 (+30.5%), $6.22 million in FY2023 (+66.1%), $3.75 million in FY2022 (+75.7%) and $2.13 million in FY2021 (+297.0%).
  • The Q2 2026 figure stands as the lowest quarterly Depreciation & Amortization (CF) since Q1 2024.
  • On a year-over-year basis, Depreciation & Amortization (CF) increased in five of the last eight quarters, with growth averaging 3.7%.
  • The strongest year-over-year quarter for Depreciation & Amortization (CF) in the past five years was Q4 2021, with growth of 262.8%; the weakest was Q2 2026, with a decline of 10.1%.
  • According to Business Quant data, Depreciation & Amortization (CF) for the three prior quarters was $2.03 million (Q1 2026), $2.13 million (Q4 2025) and $2.1 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Dep. & Amort. (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 1.96 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 194.00 Mn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 599.00 Mn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 1.93 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 1.11 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 98.00 Mn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 1.62 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 56.50 Mn
10 Monte Rosa Therapeutics 1.02 Bn 428.56 Mn - 1.91 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1.91 Mn
Mar 31, 2026 2.03 Mn
Dec 31, 2025 2.13 Mn
Sep 30, 2025 2.10 Mn
Jun 30, 2025 2.13 Mn
Mar 31, 2025 2.05 Mn
Dec 31, 2024 2.06 Mn
Sep 30, 2024 2.10 Mn
Jun 30, 2024 2.06 Mn
Mar 31, 2024 1.90 Mn
Dec 31, 2023 1.85 Mn
Sep 30, 2023 1.83 Mn
Jun 30, 2023 1.39 Mn
Mar 31, 2023 1.20 Mn
Dec 31, 2022 1.07 Mn
Sep 30, 2022 1.03 Mn
Jun 30, 2022 889,000.00
Mar 31, 2022 800,000.00
Dec 31, 2021 809,000.00
Sep 30, 2021 600,000.00
API Access

Monte Rosa Therapeutics Depreciation & Amortization (CF) API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=depreciation-and-amortization-cf&ticker=GLUE&period=max&api_key=YOUR_API_KEY